Company: Verastem Oncology
Job title: Chief Scientific Officer
Dr. Pachter has over 30 years of experience leading discovery and translational research for small molecule and monoclonal antibody anti-cancer therapeutics. He joined Verastem in 2011, and has led research targeting RAS-dependent cancers and immunosuppressive cell populations for treatment of human cancers with the company’s clinical stage RAF/MEK, FAK and PI3K inhibitors. He was previously Head of Cancer Biology at OSI Pharmaceuticals where his team focused on kinase inhibitors, including erlotinib, for treatment of solid tumors. Prior to OSI, Dr. Pachter held positions of increasing responsibility at Schering-Plough, progressing 3 agents into development and making key contributions to the regulatory approval of temozolomide. Dr. Pachter did postdoctoral work at Yale University School of Medicine, holds a Ph.D. from Baylor College of Medicine, and is an author of over 60 publications.
Unique Dual RAF/MEK Inhibitor VS-6766 for KRAS Mutant NSCLC 5:20 pm
• Combination of VS-6766 with FAK inhibitor for KRAS G12V mt NSCLC – preclinical rationale • Combination of VS-6766 with FAK inhibitor for KRAS G12V mt NSCLC – clinical data • Combination of VS-6766 with a G12C inhibitor for KRAS G12C mt NSCLCRead more
day: Day One